HPLC-UV analytical method for determination of pizotifen after in vitro transdermal diffusion studies

Biomedical Chromatography

Volumn 26, Issue 6, 2012, Pages 769-774

  Serna Jimenez C E ^a   del Rio Sancho, S ^a   Calatayud Pascual, M A ^a   Balaguer Fernandez C ^a   Femenia Font A ^a   Lopez Castellano A ^a   Merino, V ^b  

^a UNIVERSIDAD CEU CARDENAL HERRERA   (Spain)

^b UNIVERSITAT POLITÈCNICA DE VALÈNCIA   (Spain)

Author keywords

High performance liquid chromatography; Pizotifen malate; Stability; Transdermal diffusion; Validation

Indexed keywords

DIFFUSION;

ANALYTICAL METHOD; DIFFUSION STUDIES; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY; IN-VITRO; LIMIT OF DETECTION; LIMIT OF QUANTIFICATIONS; PIZOTIFEN MALATE; TRANSDERMAL; TRANSDERMAL DIFFUSION; VALIDATION;

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

PIZOTIFEN MALEATE;

ARTICLE; DRUG DETERMINATION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; QUANTITATIVE ANALYSIS; ROOM TEMPERATURE; ULTRAVIOLET RADIATION; VALIDATION STUDY;

EID: 84860473507     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1727     Document Type: Article

References (21)

1. Abounassif MA, El-Obeid HA and Gadkariem EA. Stability studies on some benzocycloheptane antihistaminic agents. Journal of Pharmaceutical and Biomedical Analysis 2005; 36(5): 1011-1018; doi: 10.1016/j.jpba.2004.09.019
2. Briars GL, Travis SE, Anand B and Kelly AM. Weight gain with pizotifen therapy. Archives of Disease in Childhood 2008; 93(7): 590-593; doi: 10.1136/adc.2007.128611
3. Cleland PG, Barnes D, Elrington GM, Loizou LA and Rawes GD. Studies to assess if pizotifen prophylaxis improves migraine beyond the benefit offered by acute sumatriptan therapy alone. European Neurology 1997; 38(1): 31-38.
4. Dolecek R and Janstová V. Long-term effect of pizotifen treatment on growth hormone levels of underweight children, including those with anorexia nervosa. Pharmatherapeutica 1985; 4(2): 81-87.
5. Eiland LS, Jenkins LS and Durham SH. Pediatric migraine: pharmacologic agents for prophylaxis. The Annals of Pharmacotherapy 2007; 41(7): 1181-1190; doi: 10.1345/aph.1K049
6. El-Kousy N and Bebawy LI. Determination of some antihistaminic drugs by atomic absorption spectrometry and colorimetric methods. Journal of Pharmaceutical and Biomedical Analysis 1999; 20(4): 671-679; doi: S0731-7085(99)00040-0 [pii]
7. Femenia-Font A, Merino V, Rodilla V and Lopez-Castellano A. High-performance liquid chromatographic determination of sumatriptan after in vitro transdermal diffusion studies. Journal of Pharmaceutical and Biomedical Analysis 2005; 37(3): 621-626; doi: 10.1016/j.jpba.2004.11.029
8. Franz T. The finite dosis technique as a valid in vitro model for the study of percutaneous absorption. Current Problems in Dermatology 1978; 7: 58-68.
9. Jenke D. Chromatographic method validation: a review of current practices and procedures. I. Guidelines for primary validation parameters. Journal of Liquid Chromatography and Related Technolgies 1996a; 19: 719-736.
10. Jenke D. Chromatographic Method Validation: a review of current practices and procedures. II. Guidelines for primary validation parameters. Journal of Liquid Chromatography & Related Technolgies 1996b; 19: 737-757.
11. Lister AS. Validation of HPLC methods in pharmaceutical analysis. Separation Science and Technology 2005; 6: 191-217.
12. Marro D, Guy RH and Delgado-Charro MB. Characterization of the iontophoretic permselectivity properties of human and pig skin. Journal of Controlled Release 2001; 70(1-2): 213-217; doi: S0168365900003503 [pii]
13. Miller JC and Miller JN. Statistics for Analytical Chemistry. Ellis Horwood: Chichester, 1993.
14. Olesen J. A review of current drugs for migraine. Journal of Neurology 1991; 238: S23-S27.
15. Rahman SM, Lutfulkabir A, Jahan MD, Momen AZ and Rouf AS. Validation and application of reversed phase high-performance liquid chromatographic method for quantification of pizotifen malate in pharmaceutical solid dosage formulations. Pakistan Journal of Pharmaceutical Sciences 2010; 23(4): 435-441.
16. Silcocks P, Whitham D and Whitehouse WP. P3MC: a double blind parallel group randomised placebo controlled trial of propranolol and pizotifen in preventing migraine in children. Trials 2010; 11: 71; doi: 10.1186/1745-6215-11-71
17. Snow V, Weiss K, Wall EM and Mottur-Pilson C. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Annals of Internal Medicine 2002; 137(10): 840-849; doi: 200211190-00014 [pii]
18. Vander Heyden Y, Nijhuis A, Smeyers-Verbeke J, Vandeginste B and Massart D. Guidance for robustness/ruggedness tests in method validation. Journal of Pharmaceutical and Biomedical Analysis 2001; 24(5-6): 723-753; doi: 10.1016/s0731-7085(00)00529-x
19. van de Sandt JJ and Rutten AA. Differential effects of chemical irritants in rabbit and human skin organ cultures. Toxicology in Vitro 1995; 9(2): 157-168; doi: 0887-2333(94)00201-5 [pii]
20. Vávrová K, Lorencová K, Klimentová J, Novotný J and Hrabálek A. HPLC method for determination of in vitro delivery through and into porcine skin of adefovir (PMEA). Journal of Chromatogry B 2007; 853(1-2): 198-203; doi: 10.1016/j.jchromb.2007.03.012
21. Yoon MS, Savidou I, Diener HC and Limmroth V. Evidence-based medicine in migraine prevention. Expert Review of Neurotherapeutics 2005; 5(3): 333-341; doi: 10.1586/14737175.5.3.333